RETATRUTIDE 20MG KIT

RETATRUTIDE (also known by its research code LY3437943) is an investigational peptide medication that acts as a triple-receptor agonist to treat obesity and type 2 diabetes. It is not yet approved by the FDA for any use, though it is in late-stage clinical trials.

HOW IT WORKS

Retatrutide is a "triple G" agonist, meaning it mimics the actions of three natural hormones in the body simultaneously:

GLP-1 (Glucagon-like peptide-1): Helps lower blood sugar, slow gastric emptying, and reduce appetite.

GIP (Glucose-dependent insulinotropic polypeptide): Also helps regulate blood sugar by promoting insulin release and contributes to appetite reduction.

Glucagon: Promotes the breakdown of stored fat for energy use, increasing energy expenditure.

This triple action distinguishes it from other weight loss drugs like semaglutide (Ozempic/Wegovy), which only targets GLP-1 receptors, and tirzepatide (Mounjaro/Zepbound), which targets GLP-1 and GIP receptors.

EFFICACY AND STATUS

Clinical trials have shown promising results, with participants experiencing an average weight loss of up to 24.2% over 48 weeks at the highest dose.

IMPORTANT CONSIDERATIONS:

Not FDA Approved: Retatrutide is still in Phase 3 clinical trials, led by Eli Lilly. Final approval is not expected until at least mid-to-late 2026 or early 2027.

Unregulated Online Sales: The FDA has warned against unapproved products sold online as "retatrutide peptide". These are unregulated research chemicals not intended for human use and can be unsafe and unreliable.

COMMON SIDE EFFECTS: The most common side effects reported in trials are gastrointestinal, including nausea, diarrhea, vomiting, and constipation.